Pharmaceutical Firms Agree to Continue Support for Canadian Program That Supplies Generic Drugs to Rwanda
October 20, 2009
Pharmaceutical companies GlaxoSmithKline and the Canadian subsidiaries of Shire and Boehringer Ingelheim "said Monday they support continued efforts by a Canadian generic drug maker [Apotex] to distribute cheaper versions of their patented HIV/AIDS medicines in Rwanda," Agence France-Presse reports. But so far, only Rwanda has received drugs from the arrangement, known as Canada's Access to Medicines Regime (CAMR). Apotex "threatened last month to abandon the project, saying it was a too 'costly and complicated process.'" It called for CAMR rules to be simplified (10/19).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.